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Abstract: The authors report herein two diagnostically challenging cases centered on the myeloid/natural killer 
(myeloid/NK) cells, a variant of myeloblasts, to illustrate the importance of advanced flow cytometric 
immunophenotyping and an updated understanding of surface markers in hematopoietic malignancies. 
Myeloid/NK cell acute leukemia is a very rare subtype of leukemia. Although its NK-cell nature is debatable, it 
represents a variant of leukemia with distinct morphological and immunophenotypical features. The first case is a 
de novo myeloid/NK-cell acute leukemia with a striking clinical, morphologic and immunophenotypic resemblance 
to acute promyelocytic leukemia (APL), but which could be distinguished by its CD11a, CD18, CD117 and CD9 
expression. This case illustrates the importance of utilizing the APL surrogate surface phenotype of HLA-DRlow, 
CD11alow and CD18low by flow cytometric study to rule in/out APL immunophenotypically. In the second case, we 
show that myeloid/NK-cell blasts can present as a variant of blasts in a preleukemic disease as refractory anemia 
with excess blasts-1 (RAEB-1), where the blasts were negative for CD34, CD117 and HLA-DR. The recognition of 
such blast variant is important in appropriately classifying such preleukemic diseases by blast percentage. 




Myeloid/natural killer (myeloid/NK) cell acute 
leukemia was first reported by Scott et al [1] in 
1994 as a subtype of acute leukemia with 
distinct morphological and immuno-
phenotypical features. Although its NK-cell 
nature is largely in debate given our recent 
understanding of myeloid and NK-cell 
differentiation, it is nevertheless characterized 
by a unique immunophenotype: CD33+, CD56+, 
CD11a+, CD13low+, CD15low+, CD34±, HLA-DR-, 
CD16-, and unique morphologic features: 
deeply invaginated nuclear membranes, scant 
cytoplasm with fine azurophilic granularity, and 
finely granular Sudan black B and 
myeloperoxidase (MPO) cytochemical reactivity. 
These morphological features and immuno-
phenotype are remarkably similar to those of 
APL, particularly the microgranular variant  
__________ 
The opinions and/or assertions contained herein are 
solely those of the authors and should not be construed as 
official, or as representing the views of the United States 
Government or any of its subsidiaries. 
(M3v). However, all the cases that were tested 
lacked the t(15;17) or the promyelocytic 
retinoic acid receptor (RARα) fusion transcript 
detected by reverse transcriptase- polymerase 
chain reaction (RT-PCR), and failed to show a 
differentiation-induction response to all-trans 
retinoic acid (ATRA) in vitro. The treatment 
outcome was comparable to that expected for 
AML patients treated with daunorubicin and 
cytosine arabinoside, with a median survival of 
30 months. 
 
Following the initial description by Scott et al, 
only a few single case reports have been 
published [2-5]. The case reported by Lee JJ et 
al [3] represented a case of myeloid/NK 
leukemia developing in a patient with 
preexisting T-cell lymphoma. Kaya et al [2] 
described a case of myeloid/NK cell acute 
leukemia with an immunophenotype of CD33+, 
CD56+, CD16-, HLA-DR- which was preceded by 
multiple myeloma. In a letter to the editor, 
Paietta et al [6] reported 2 cases of AML 
showing an immunophenotype of HLA-DR−, 
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CD34−, CD33+, CD13+, CD56+, CD11a+ and 
CD16−, but both cases harbored the long form 
of the PML/RARa fusion transcript, suggesting 
that some of the myeloid/NK leukemia might 
be authentic M3. In addition, such variant 
blasts have never been described in 
association with other preleukemic diseases, 
such as a myelodysplastic syndrome (MDS).  
 
Here we report a case of de novo acute 
leukemia with an immunophenotype and 
morphology similar to the myeloid/NK-cell 
acute leukemia initially described by Scott et al, 
and a case of refractory anemia with excess 
blasts (RAEB)-1 where the blasts showed 
myeloid/NK-cell characteristics. Both cases 






A 40 year old female presented with fever, 
chills, night sweats over a two-week period, 
precipitated by pleuritic chest pain and 
hemoptysis. She was admitted to the 
emergency room where she was found to have 
leukocytosis and thromobocytopenia.  A 
complete blood count (CBC) showed white 
blood cell (WBC) 89.9 x109/L, hemoglobulin 
(Hb) 9.6 g/dL, platelets 73 x 109/L with 3% 
neutrophils, 5% promyelocytes, 2% monocytes, 
and 85% “blasts”.  Coagulation studies 
revealed very high fibrin degradation products 
(FDP) and D-dimer, and low antithrombin III 
activity, indicative of pathologic fibrinolysis and 
severe disseminated intravascular coagulation 
(DIC). Peripheral smear revealed numerous 
immature cells with invaginated nuclear 
membranes, inconspicuous to prominent 
nucleoli, and scant to moderate hypogranular/ 
agranular cytoplasm (Figure 1). 
 
Flow cytometric study (Beckman Coulter FC-
500) performed on peripheral blood sample 
showed that the immature cells were positive 
for CD33, CD56, CD71low, but negative for 
CD34, HLA-DR, CD117, CD2, CD3, CD4, CD5, 
CD7, CD8, CD10, CD13, CD15, CD16, CD11b, 
CD64, CD14 and CD1a. Intracytoplasmic and 
nuclear stains performed by flow cytometry 
following permeabilization showed the blasts 
were positive for MPO, negative for Tdt, 
cytoplasmic CD3, or cytoplasmic CD22. The 
immunophenotype and morphology in the 
clinical setting of coagulopathy raised the 
possibility of APL, microgranular variant. 
 
 
Figure 1 Peripheral blood smear showing blasts 
with deeply invaginated nuclear membrane and 
some bilobed nuclei (Wright & Giemsa stain, 
original magnification x1000). 
 
Additional markers designed for APL were thus 
tested to show that the leukemic cells were 
CD11a+ (>85% cells), CD18+ (>85% cells), and 
CD9+ (50% cells). Conventional karyotyping 
showed a normal female karyotype. Neither 
t(15;17) nor other rearrangement involving 
RARa or PML gene was detected following 
fluorescence in situ hybridization (FISH) 
technique using DNA (ONCOR) hybridizing to 
RARa (17q12) and PML (15q22).  
 
A diagnosis of myeloid/NK-cell acute leukemia 
was rendered. It was classified as AML-M1 
according to the French-American-British (FAB) 
classification, and AML, not otherwise 
categorized (NOS)-M1 according to the world 
health organization (WHO) criteria. She 
received hydroxyurea resulting in 50% 
leukoreduction, followed by standard induction 
chemotherapy composed of 3 days of 
daunorubicin and 7 days of cytarabine. She 
achieved complete remission at day 30. Her 
consolidation chemotherapy consisted of 
mitoxantrone and VP-16, and she has been 




The patient was a 77 year old male who 
presented with fatigue to his primary care 
physician. His CBC showed WBC 2.0 x 109/L, 
Hb 9.3 g/dL; platelets 43 x 109/L with 77% 
neutrophils, 1% monocytes, and 22% 
lymphocytes. He was referred to our medical 
center where a bone marrow biopsy was 
performed. His bone marrow showed a 70% 
cellularity with many dysplastic mega-
karyocytes (Figure 2B). The bone marrow 
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Figure 2 A. The bone marrow aspirate showed increased blasts ranged in size with invaginated/convoluted 
nuclear membrane, as pointed by the arrows (Wright stain, original magnification x1000). B. The bone marrow 
biopsy showed approximately 70% cellularity with dysplastic megakaryocytes (H&E, original magnification x400). 
C. CD34 immunohistochemical stain highlighted only “conventional” CD34+ positive blasts (original magnification 
x400). D-F. Flow cytometric study showed increased CD45 immature cells (highlighted in red) on side scattered vs 
CD45 plot (D); the “conventional” blasts (0.6%) are CD34+CD117+CD56- and myeloid/NK cell blasts (6.2%) are 
CD34-CD117-CD56+ (E and F).   
 
 
aspirate smears revealed increased blasts 
that ranged in size with hypogranular/aganular 
cytoplasm, and some had invaginated/ 
convoluted nuclear membrane (Figure 2A). 
Granulocytic and megakaryocytic dysplasia 
was apparent. A total of 4.2% CD45low+ 
immature cells were detected by flow 
cytometric analysis, of which, 3% cells with an 
immunophenotype of CD33+, CD56+, CD34-, 
HLA-DR-, CD13-, CD117-, CD16-, CD11b-, CD64-, 
CD2-, CD3-, CD7- and 1.2% cells with an 
immunophenotype of CD34+, HLA-DR+, 
CD117+, CD33+, CD13+, CD56- were seen. A 
CD34 immunohistochemical stain was 
performed on bone marrow biopsy, revealing 
approximately 1-2% positive cells (Figure 2C). 
Conventional karyotyping showed trisomy 8 in 
2 out of 30 metaphase cells examined 
{47,XY,+8[2]/46,XY[28]}. Interphase FISH was 
performed with a probe to the chromosome 8 
centromere to reveal trisomy 8 in 9 out of 100 
cells. The case was classified as RAEB-1 based 
upon persistent clinical cytopenia, the 
presence of dysplasia and increased blasts. 
He was enrolled in a pilot study and treated 
with the experimental drug thalidomide and 
azacitidine (Vidaza). A follow-up bone marrow 
biopsy performed 11 months after the initial 
diagnosis showed a cellularity of 70-80% with 
similar degree of morphological dyaplasia. The 
Int J Clin Exp Pathol (2008) 1, 544-549 546 
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bone marrow contained 8% blasts based on 
bone marrow aspirate differential count. Flow 
cytometric analysis showed 6.2% blasts with 
an immunophenotype of CD33+, CD56+, CD34-, 
HLA-DR-, CD13-, CD117-, CD16-, CD11b- and 
0.6% blasts of CD34+, HLA-DR+, CD117+, 
CD33+, CD13+ and CD56- (Figures 2D, 2E and 
2F). Chromosomal study performed on the 
follow-up bone marrow showed a normal 
karyotype 46, XY[20]. FISH study with a probe 
to the chromosome 8 centromere revealed 
trisomy 8 in 3/100 cells. The patients 
remained red cell transfusion-dependant. 
Seventeen months after diagnosis, he died of 
anemia accompanied by upper gastro-
intestinal bleeding. There was no evidence of 




Here we reported a case of acute leukemia 
and a case of RAEB-1, where the blasts 
showed typical myeloid/NK-cell characteristics 
as initially described by Scott et al [1]. Both 
cases are extremely rare and posed great 
diagnostic challenges.  
 
Following the initial description by Scott et al, 
Suzuki et al [7] reported 7 cases of 
“myeloid/NK-cell precursor” acute leukemia 
that showed an immunophenotype of CD7+, 
CD33+, CD34+, CD56+, frequently HLA-DR+, 
MPO- and a lymphoblastic (L2) morphology. 
Subsequently reported cases in the literature 
on myeloid/NK acute leukemia entity were 
mainly of the latter form, which have been 
found to not be an uncommon type of AML 
and which have been classified under M0 by 
FAB and WHO.  Myeloid/NK precursors were 
also reported in Philadelphia chromosome-
positive chronic myelogenous leukemia (CML) 
blast crisis [8, 9]. In contrast, myeloid/NK-cell 
acute leukemia was only rarely reported [2-5] 
after the initial description by Scott et al. 
Moreover, it has never been reported as a 
variant blasts in pre-leukemic diseases, such 
as MDS.  
 
Out of the 158 new acute myeloid leukemia 
cases diagnosed at our institute over the last 5 
years, our case 1 was the only case showing 
an immunophenotype and morphology similar 
to myeloid/NK-cell acute leukemia described 
by Scott [1].  The case showed a substantial 
clinical, morphologic and immunophenotypic 
similarity to APL. However, the current 
understanding of APL surface markers by flow 
cytometry enabled us to differentiate APL from 
other CD34-HLA-DR- acute leukemia. Paietta et 
al has discovered that PML/RARαpos APL cells 
typically lack leukocyte integrins. The HLA-
DRlow, CD11alow, CD18low phenotype provides a 
reliable surrogate antigen expression profile 
for PML/RARαpos APL, irrespective of 
morphology and transcript isoform with 100% 
accuracy [10]. Other markers also show 
differential expression in APL and myeloid/NK-
cell leukemia, such as CD117, which is often 
expressed in a high percentage of APL cases 
[10]. APL also often shows CD9 expression in 
more than 75% blasts; and CD2 co-expression 
has been associated with M3v morphology 
and/or S-isoform [10]. In our case, the myeloid 
NK-cells were CD117-, CD11a+ (>85% cells), 
CD18+ (>85% cells), and CD9+ in only 50% 
cells, differing from APL. Based upon this 
immunophenotype, the case was diagnosed as 
non-APL but myeloid/NK-cell acute leukemia, 
which should be considered as a variant AML 
and classified as AML-NOS-M1 according to 
WHO criteria. FISH confirmed the absence of 
any RARα gene rearrangement which also 
excluded APL-like subset where RARα is fused 
with different partners, such as promyelocytic 
leukemia zinc finger, nucleophosmin, or 
nuclear mitotic apparatus. In 2004, Kussick et 
al [11] described a subtype of acute leukemia 
that showed some morphological and immuno-
phenotypical resemblance to myeoid/NK cell 
leukemia. There was a high frequency of 
internal tandem duplication (ITD) of the Flt3 
gene in their series. Unfortunately, there was 
no material remained to test for Flt3 ITD in our 
case. 
 
Case 2 illustrates that myeloid/NK-cells can be 
present as a variant of blasts in preleukemic 
disorders such as MDS. The blasts had similar 
morphologic features and immunophenotypic 
characteristics as seen in myeloid/NK-cell 
acute leukemia. Often, the blasts in MDS 
exhibit an immunophenotype of committed 
myeloid precursors (CD34+, CD38+, HLA-DR+, 
CD13+ and CD33+), regardless of the MDS 
subtype [12].  The presence of myeloid/NK 
blasts could cause diagnostic confusion, and 
result in an underestimation of the blast 
number, especially when the bone marrow 
aspirate smears are suboptimal for an 
accurate manual blast counting. A CD34 
and/or CD117 immunohistochemical stain 
performed on a bone marrow biopsy specimen 
may be misleading.  It is also important not to 
misinterpret basophils as myeloid/NK-blasts 
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because they share some immunopheno-
typical features with myeloid/NK blasts and 
can be significantly increased in preleukemic 
disorders, such as a myeloproliferative disease 
and MDS. Basophils have an immunohpheno-
type of CD45low+, CD34-, HLA-DR-, CD117-, 
CD13+, CD33+, CD18+, but CD11b+, CD56-, 
CD25+ and CD9+ [13]. Another interesting 
finding in this case was the presence of 
trisomy 8, a typical chromosomal abnormality 
in MDS [14], in a small subset marrow cells 
(9/100 by interphase FISH). The number of 
trisomy 8 cells decreased as myeloid/NK cell 
population expanded, indicating the 
myeloid/NK-blasts were likely to be non-
trisomy 8. A similar finding was described in 2 
cases of CML with transformation to 
Philadelphia chromosome-negative myeloid/ 
NK-precursor leukemia [15]. 
 
In summary, although the term of “myeloid/NK 
cells” may be misnomer, it is diagnostically 
necessary to recognize such variant blasts. 
The first case we presented here revisited the 
topic of myeloid/NK cell acute leukemia, 
acknowledged its resemblance to APL 
morphologically, immunophenotypically and 
clinically, but also illustrated that they could be 
distinguished by advanced flow cytometric 
immunophenotyping. In the second case we 
first showed that myeloid/NK-cells could 
present as a variant of blasts in MDS. The lack 
of CD34, CD117 and HLA-DR may lead to 
underestimation of the blast number in such 
cases. Both cases were diagnostically 
challenging and required updated under-
standing of the surface markers in hemato-
poietic malignancies. 
 
Please address all correspondences to Sa A. Wang, 
MD, Department of Pathology, 3 Biotech 1 
Innovation Drive, Worcester, MA 01605, USA. Tel: 
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